<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01069965</url>
  </required_header>
  <id_info>
    <org_study_id>BGP-15-CLIN-IR04</org_study_id>
    <secondary_id>2009-013328-21</secondary_id>
    <nct_id>NCT01069965</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Parallel Group, Multiple Dose, Multicenter Study to Assess Safety &amp; Efficacy of BGP-15 Administered Orally 1 or 2 Times Daily With Metformin &amp; Sulfonylurea or Metformin in T2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>N-Gene Research Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Msource Medical Development GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kinexum LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thermo Fisher Scientific</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haupt Pharma Wülfing GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barc NV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>N-Gene Research Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety and dose finding efficacy study to evaluate the effects of BGP-15 over the
      dose range of 100 mg/day to 400 mg/day. Doses are applied once or twice a day for 13 weeks as
      add-on therapy to the combination of metformin and sulfonylurea treatment or metformin alone
      in patients with Type 2 Diabetes Mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel group, multiple dose,
      multicenter study with 5 treatment arms and 1 placebo arm. Patients should be treated with
      both metformin and SU or metformin alone. Patients will be randomized to 100,100 + 100, 200,
      200 + 200, and 400 mg/day or placebo, as an add-on to their current treatment. The study
      consists of 2 periods:

        -  A 14-day screening period for ascertaining the inclusion/exclusion criteria; and,

        -  A 13-week treatment period with different doses of BGP-15 or placebo as an add-on
           therapy to metformin and SU treatment or metformin treatment alone.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding support withdrawn.
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Glycosylated Hemoglobin at Week 13</measure>
    <time_frame>Baseline and Week 13</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Plasma Glucose at Weeks 4, 8, 13</measure>
    <time_frame>Baseline and Weeks 4, 8, and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Plasma Glucose at Week 13</measure>
    <time_frame>Baseline and Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular and metabolic biomarkers at Baseline and 13 weeks</measure>
    <time_frame>Baseline and Week 13</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">196</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>6. BGP-15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg BGP-15 + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5. BGP-15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg BGP-15 BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4. BGP-15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg BGP-15 + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. BGP-15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 50 mg BGP-15 capsules by mouth in the morning; and two 50 mg BGP-15 capsules by mouth in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. BGP-15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg BGP-15 + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1. Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGP-15 100 mg QD</intervention_name>
    <description>Two 50 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening</description>
    <arm_group_label>2. BGP-15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGP-15 100 mg BID</intervention_name>
    <description>One 100 mg BGP-15 capsule by mouth in the morning; and one 100 mg BGP-15 capsule by mouth in the evening</description>
    <arm_group_label>3. BGP-15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo BID</intervention_name>
    <description>Two Placebo capsules by mouth in the morning; and two Placebo capsules by mouth in the evening</description>
    <arm_group_label>1. Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGP-15 200 mg QD</intervention_name>
    <description>Two 100 mg BGP-15 capsule by mouth in the morning; and two Placebo capsule by mouth in the evening</description>
    <arm_group_label>4. BGP-15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGP-15 200 mg BID</intervention_name>
    <description>Two 100 mg BGP-15 capsules by mouth in the morning; and two 100 mg BGP-15 capsules by mouth in the evening</description>
    <arm_group_label>5. BGP-15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGP-15 400 mg QD</intervention_name>
    <description>Two 200 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening</description>
    <arm_group_label>6. BGP-15</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

        Patients meeting all of the following criteria will be eligible for enrollment:

          1. Male and female patients with T2DM at time of diagnosis as defined by the American
             Diabetes Association (ADA) criteria;

          2. Age between 30 and 70 years (inclusive);

          3. HbA1c ≥7.5% - ≤12.0% at Screening, Visit 1;

          4. FPG ≤270 mg/dL (15.0 mmol/L);

          5. Body mass index (BMI) &gt;27 and ≤40 kg/m2;

          6. Current treatment with either metformin alone or in combination with SU. The dose of
             the current treatment must be stable for at least 8 weeks prior to randomization.
             Patients being treated with metformin must be at their optimal or near-optimal dose
             (≥1500 mg/day ± 500 mg/day for a range of 1000 to 2000 mg/day), and patients being
             treated with SU must be receiving at least one half of the maximum approved SU dose;

          7. Women may be enrolled if all three of the following criteria are met:

               1. They have a negative serum pregnancy test at Screening;

               2. They are not breast feeding; and,

               3. They do not plan to become pregnant during the study AND if one of the following
                  three criteria is met:

             i. They have had a hysterectomy or tubal ligation at least 6 months prior to signing
             the informed consent form; ii. They have been postmenopausal for at least 1 year; or,
             iii. They are of childbearing potential and will practice one of the following methods
             of birth control throughout the study: injectable or implantable hormonal
             contraception or intrauterine device; or two of the following methods of birth control
             throughout the study: oral or patch contraception plus a barrier contraceptive (eg,
             diaphragm plus spermicide, male or female condom plus spermicide, or vasectomized male
             partner). Abstinence, partner's use of condoms, and vasectomy are NOT acceptable
             methods of contraception;

          8. Willingness to sign an informed consent document; and,

          9. No conditions that hinder participation in the trial, as determined by the
             Investigator and Sponsor.

        Exclusion criteria

        Patients meeting any of the following criteria will be ineligible for enrollment:

          1. Treatment with peroxisome proliferator-activated receptor (PPAR) agonists (including
             fibrates) within the last 3 months;

          2. Treatment with dipeptidyl peptidase 4 (DPP-4) inhibitors, acarbose, or incretins
             within the last 3 months;

          3. Chronic use of insulin injections within the last 1 month;

          4. Hypoglycemia requiring third party assistance within the last 3 months;

          5. Impaired hepatic function measured as alanine aminotransferase (ALAT) &gt;2X the upper
             reference limit;

          6. Impaired renal function measured as serum creatinine &gt;150 umol/L (1.7 mg/dL);

          7. Decompensated heart failure (New York Heart Association [NYHA] class III and IV);

          8. Unstable angina pectoris or myocardial infarction within the last 12 months;

          9. Clinically significant ECG abnormalities at screening including QTc interval
             (Bazett's) ≥450 msec or AV block &gt;1st degree;

         10. Uncontrolled, treated or untreated hypertension (systolic blood pressure [BP] ≥160
             mmHg and/or diastolic BP ≥100 mmHg);

         11. Any condition that the Investigator and/or Sponsor feel would interfere with trial
             participation or evaluation of the results eg, drug abuse or serious disease such as
             acquired immunodeficiency syndrome/human immunodeficiency syndrome (AIDS/HIV)
             antibodies, Hepatitis B, or Hepatitis C;

         12. Pregnancy or breastfeeding, the intention to become pregnant, or judged to be using
             inadequate contraceptive measures;

         13. History of alcohol and/or drug dependence within the last 2 years;

         14. Receipt of any investigational drug or medical device within 3 months prior to this
             trial;

         15. Fasting triglycerides &gt;700 mg/dL at screening; or,

         16. Diagnosis or treatment of cancer within the past 5 years except for excision of basal
             cell or squamous cell skin lesions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Damsbo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kinexum LLC, Harper's Ferry, WV, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Ratner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medstar Research Institute, Hyattsville, Maryland, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ioanna Gouni-Berthold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laszlo Koranyi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drug Research Center, Balatonfured, Hungary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Andrew J. Lewin Medical Corporation DBA National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials, LLC.</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creekside Endocrine Associates PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic Research Institute, Inc.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Pharmaceutical Research</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICCT Research International, Inc.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medstar Health Research Institute</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research, P.C.</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Alliance Against Diabetes</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hanover Medical Research</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Medical Research, LLC.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Pharmaceutical Research</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain View Clinical Research</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Associates, Inc.</name>
      <address>
        <city>Taylors</city>
        <state>South Carolina</state>
        <zip>29687</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Athens Medical Group</name>
      <address>
        <city>Athens</city>
        <state>Tennessee</state>
        <zip>37303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juno Research, LLC.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juno Research, LLC.</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cetero Research-San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetespraxis Bad Mergentheim</name>
      <address>
        <city>Bad Mergentheim</city>
        <zip>97980</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Schätzl</name>
      <address>
        <city>Großheirath-Rossach</city>
        <zip>96269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis Diabetes</name>
      <address>
        <city>Neuwied</city>
        <zip>56564</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetologische Schwerpunktpraxis</name>
      <address>
        <city>Siegen</city>
        <zip>57072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRUG Research Center Hungary Kft.</name>
      <address>
        <city>Balatonfüred</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University 2nd Clinic for Internal Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Country Teaching Hospital, Dept of Diabetology and Metabolism</name>
      <address>
        <city>Győr</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Bugyi Istvan Hospital, Diabetology Outpatient Clinic</name>
      <address>
        <city>Szentes</city>
        <zip>6600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zala County Hospital Department of Diabetology</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <last_update_submitted>September 26, 2014</last_update_submitted>
  <last_update_submitted_qc>September 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

